Zacks Research Initiates Coverage on Fortress Biotech (NASDAQ:FBIO)

Analysts at Zacks Research assumed coverage on shares of Fortress Biotech (NASDAQ:FBIO – Get Free Report) in a research note issued to investors on Wednesday, Zacks reports. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently commented on FBIO. Wall Street Zen cut shares of Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings downgraded shares of Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $17.00.

Get Our Latest Stock Report on FBIO

Fortress Biotech Stock Performance

NASDAQ:FBIO opened at $1.78 on Wednesday. The company has a market cap of $60.16 million, a price-to-earnings ratio of 0.78 and a beta of 1.27. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.93 and a quick ratio of 3.83. The stock’s 50 day simple moving average is $2.07 and its two-hundred day simple moving average is $2.69. Fortress Biotech has a 1 year low of $1.64 and a 1 year high of $4.53.

Fortress Biotech (NASDAQ:FBIO – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.04. Fortress Biotech had a net margin of 143.04% and a return on equity of 61.84%. The business had revenue of $19.16 million during the quarter, compared to the consensus estimate of $21.57 million. As a group, equities analysts anticipate that Fortress Biotech will post 2.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Fortress Biotech news, CEO Lindsay Rosenwald purchased 64,491 shares of the stock in a transaction on Tuesday, November 17th. The stock was bought at an average price of $1.80 per share, for a total transaction of $116,083.80. Following the acquisition, the chief executive officer directly owned 4,651,332 shares of the company’s stock, valued at $8,372,397.60. This represents a 1.41% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CFO David Jin acquired 25,000 shares of the stock in a transaction dated Wednesday, November 18th. The shares were bought at an average cost of $1.91 per share, with a total value of $47,750.00. Following the completion of the purchase, the chief financial officer directly owned 1,692,761 shares in the company, valued at approximately $3,233,173.51. This trade represents a 1.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 184,328 shares of company stock worth $340,398. Corporate insiders own 28.50% of the company’s stock.

Hedge Funds Weigh In On Fortress Biotech

Institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in shares of Fortress Biotech in the 2nd quarter worth about $47,000. Renaissance Technologies LLC boosted its holdings in Fortress Biotech by 22.8% during the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 18,490 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Fortress Biotech in the 3rd quarter worth about $462,000. 96.51% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Fortress Biotech

These are some of the FBIO headlines that stood out recently:

  • Positive Sentiment: CEO Lindsay Rosenwald bought 136,723 shares across three transactions from November 17–19, spending about $253,000. CFO David Jin also bought 47,605 shares over the same period for approximately $88,000. These open-market purchases increased both executives’ holdings and may signal confidence in the company. CEO SEC filing CFO SEC filing
  • Neutral Sentiment: HC Wainwright forecast EPS of $2.66 for FY2026 and $2.37 for FY2027. The report also estimated a Q4 2026 loss of $0.15 per share; the articles did not provide a rating change or explain the basis for the annual forecasts. Analyst insights article

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.

Featured Articles

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.